Anne M. Covey, MD
Radiofrequency ablation (RFA) was associated with superior 5-year overall survival (OS) compared with stereotactic body radiotherapy (SBRT) for patients with localized hepatocellular carcinoma, according to an observational study published in the Journal of Clinical Oncology
“Earlier detection due to improved screening programs will likely increase the number of patients with small tumors eligible for RFA and SBRT,” she said. “Exciting new technology in ablation, including improved assessment of treatment margins and the ability to create larger ablation zones, and in radiation oncology, including proton therapy, continue to improve the outlook for patients with hepatocellular carcinoma.”
- Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: Analysis of the national cancer database [published online January 12, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.75.3228.
- Covey AM. Survival following radiofrequency ablation versus stereotactic body radiotherapy for early-stage hepatocellular carcinoma. J Clin Oncol [podcast]. doi: 10.1200/JCO.2017.75.3228.
... to read the full story